Post by
prophetoffactz on Jul 16, 2024 11:52am
Still in silent mode...
Merger approved.
Directors now approved with the exception of Dennis Turpin.
Peter Edwards didn't stand for re-election.
New company name now approved.
There was no overview of the past year by Ronnie and Gilles like last year and no plan presented or status update on anything. Still in silent mode. Last year AEZS presented its Q2 financials on August 9.
With the new name approved I guess they will apply immediately to get the name of the stock changed and the symbol. They can now update the website and PR material with the new branding. It would seem a presentation on the new company could take place with the new plan and new branding.
Top-line and full diagnostic trial data is scheduled for Q3 and top-line data could be imminent given the timeline to presentation of adult data previously. That data and a potential licensing deal could greatly affect the forward plan given the potential upfront money, etc.
Then there's all the expected events lined up as has been discussed: bam, bam, bam...
The S&P Biotech ETF is essentially at its 2 1/2 year high.
Comment by
Tencents on Jul 16, 2024 1:25pm
What happened at the agm is word for word what I predicted in my comment June 25 - 1,39 pm The next focus point should be the T2 financials towards end August probably there will be some updates on progress of ongoing inititiatives as well
Comment by
prophetoffactz on Jul 16, 2024 5:49pm
Only about 790,000 shares voted. Didn't take many shares to put someone over the top in the context of outstanding shares. By next year the shareholder base/voting base could be very different given the event horizon as various assets reach proof of principle. That's what the investment community needs along with validating deals and analyst support.